Clinical Trial

Reducing Vertical Transmission of Hepatitis B in Africa

Study acronym: REVERT-B
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Hepatitis B virus is an infection that can be easily transmitted from women to newborns at the time of delivery. Our objective is to identify novel options that are effective and safe in preventing perinatal transmission of hepatitis B in Africa. The REVERT-B study (Reducing Vertical Transmission of Hepatitis B in Africa) is a clinical trial designed to test a new strategy of using antiviral medication in high-risk pregnant women and newborns to reduce the risk of hepatitis B transmission. The study will measure efficacy, safety, tolerability and adherence to medication.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2021-01-07; most recent amendment 2026-06-22.
Status change: Recruiting → Active, Not Recruiting 2025-10-06
Status change: Not Yet Recruiting → Recruiting 2021-09-27
Trial Details
NCT Number NCT04704024
Lead Sponsor University of Alabama at Birmingham
Collaborators: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Conditions Hepatitis B Infection
Enrollment 450 participants
Start Date 2021-09-03
Primary Completion 2026-05-01 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-26